Rising Cases of Chromosomal Abnormalities to Drive Market

Rising Cases of Chromosomal Abnormalities to Drive Market

Non-invasive prenatal testing (NIPT), also known as cell-free DNA testing, is a valuable addition to the variety of screening tests available for the identification of fetal chromosomal abnormalities. For those who are at a greater risk of fetal chromosomal anomalies and want to conduct tests for the same, prenatal screening for fetal chromosomal abnormalities is performed.


Individuals may use NIPT to make an educated decision about whether or not to pursue diagnostic testing. The gain or loss of genetic material, which may include small fragments of chromosomes to entire chromosomes, are among the significant fetal chromosomal abnormalities.


NIPT is conducted using ultrasound detection, cell-free DNA in maternal plasma tests, and biochemical screening tests, and other methods. The NIPT tests the genetic information found in this DNA to look for a variety of abnormalities. Patients between the ages of 10 and 20 weeks of pregnancy will undergo NIPT tests. To assess chromosomal defects, these tests include the extraction of fetal DNA from maternal blood.


Key Dynamics of Non-Invasive Prenatal Testing (NIPT) Market

According to a World Health Organization (WHO) report, increasing healthcare spending is responsible for improving the healthcare industry's infrastructure. As a result, innovative tests are becoming more accessible and affordable, which will help the development of the non-invasive prenatal testing industry. The demand is driven by an increase in reimbursements for the NIPT industry, as well as a move away from invasive to non-invasive methods and a rise in maternal age.


Also, the market is being fueled by the introduction and advancement of mature and emerging technologies, as well as non-invasive parenteral testing products. The demand for the non-invasive prenatal testing market is witnessing a surge in the number of collaborations. The companies are working together to bring NIPT to patients and doctors all over the world. The majority of these strategic growth efforts are aimed at improving availability, cost-effectiveness, and genetic strategies to support educational programs.


Non-Invasive Prenatal Testing (NIPT) Market Regional Opportunities

The increasing adaptability of NIPT in developing countries provides market players with numerous development opportunities. Increased average maternal age and an increasing emphasis on early fetal testing are likely to drive growth in these countries. While developing countries such as China and India have large populations, they lack advanced healthcare and genetic counseling for NIPT.


Moreover, the incident cases of chromosome and genetic disorders such as Edward syndrome and Down syndrome in these countries are on the rise. It is mainly due to highly-priced NIPT testing and lack of awareness about mutations occurring in the genes.


On the other side, in the Middle East & Africa, the healthcare solutions are not upgraded, so the test sample is required to be shipped to other countries for analysis. Therefore, to counter these issues, several private and public organizations are taking numerous initiatives to raise awareness regarding prenatal testing.


Competitive Landscape of Non-Invasive Prenatal Testing (NIPT) Market

The market is fiercely competitive, with every player competing for market share. Intense rivalry, rapid technological advances, frequent shifts in government policy, and price fluctuations are all factors that the industry must contend with for ensuring stability in the market.


Major market players are focusing on strategies of alliances, partnerships, collaborations, and expansions to improve their product availability and distribution networks in these countries to meet the increasing need for early diagnosis and exploit market growth opportunities.


Some of the major players present in the non-invasive prenatal testing market are Beijing Genomics Institute, Agilent Technologies, Inc., GE Healthcare, Koninklijke Philips N.V., Thermo Fisher Scientific, Inc., F. Hoffman-La Roche Ltd., Quest Diagnostics, Pacific Biosciences of California, Inc., Yourgene Health, Natera, Inc., and Perkinelmer, Inc.


Deep-dive Insights on Non-Invasive Prenatal Testing (NIPT) Market by Polaris Market Research: https://www.polarismarketresearch.com/industry-analysis/non-invasive-prenatal-testing-nipt-market/request-for-sample

Leverage Our Services

Attainment of client satisfaction being our motto, we at Polaris are happy to offer you multitude of reasons for why you should select us for your businesses.

  • Uninterrupted Service Commitment

    Our commitment to our clients lies not only from the inception of our pre-on boarding discussions but also beyond the completion and delivery of our services.

  • Custom Research

    We categorically offer custom-made/ tailored services for our syndicated research reports to provide you insights to meet the strategic requirements of your organization.

  • Quality Assured

    On lines of the industry best-practices, we offer our clients the finest in research and consulting services with the most reliable and accurate research findings.